Related Experiment Video

Updated: Aug 22, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.5K

Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer

Stephen Y C Choi1,2,3, Caroline Fidalgo Ribeiro4, Yuzhuo Wang1,2,3

  • 1Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.

Biomolecules
|November 11, 2022
PubMed

Insights

New therapeutic targets are needed for lethal castration-resistant prostate cancer. This study explores tumor metabolism, gene regulation, and the tumor microenvironment to identify vulnerabilities and develop new treatments.

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Prostate Cancer Research

Background:

  • Lethal castration-resistant prostate cancer (CRPC) urgently requires novel therapeutic targets beyond the androgen receptor (AR).
  • Tumor metabolism is a critical hallmark of cancer, driving oncogenesis and influencing treatment resistance.
  • Understanding the interplay between metabolic features, AR signaling, genetic drivers, and the tumor microenvironment is crucial for identifying vulnerabilities in prostate cancer.

Purpose of the Study:

  • To investigate the relationship between distinctive metabolic features and AR signaling in prostate cancer progression.
  • To identify metabolic vulnerabilities by analyzing the tumor microenvironment's symbiotic and competitive metabolic interactions.
  • To explore the links between metabolism, gene regulation, and the unique metabolic signatures defining malignant phenotypes in prostate tumors.

Main Methods:

  • Exploration of the intricate links between cellular metabolism and gene regulatory networks in prostate cancer.
  • Analysis of metabolic signatures associated with distinct stages of prostate tumor progression and malignant phenotypes.
  • Review of current and emerging metabolism-based pharmacological strategies for CRPC treatment.

Main Results:

  • Distinctive metabolic features are closely associated with AR signaling and genetic drivers in prostate cancer.
  • The tumor microenvironment exhibits complex metabolic interactions that can be exploited as therapeutic vulnerabilities.
  • Specific metabolic signatures correlate with malignant phenotypes and progression stages in prostate tumors.

Conclusions:

  • Targeting tumor metabolism presents a promising avenue for developing novel therapeutics for castration-resistant prostate cancer.
  • A comprehensive understanding of metabolic reprogramming and its interaction with the tumor microenvironment is key to improving CRPC outcomes.
  • Repurposing or developing metabolism-based drugs holds potential for effective CRPC treatment strategies.
Keywords:
Warburg’s effectandrogen receptorcancer metabolismdrug resistancefatty acidslactateprostate cancer

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K